Integrated workflow for rapid selection and optimization of hybridoma cell lines
contributed by ForteBio |
Hybridomas are comprised of the fusion between B-cell splenocytes from antigen-immunized mice and a myeloma tumor cell line result in immortalized antibody-producing clonal cell lines that can be screened for antigen-specific binding. Today, more than half of the commercialized antibody drugs are from hybridoma cell lines, and hybrid hybridomas have been used to produce bispecific monoclonal antibodies. Screening a hybridoma fusion and then subcloning candidate hybrids are time-consuming elements of the monoclonal antibody discovery process (Figure 1).
Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE!